sequence stringlengths 4 17.9k | seq_id stringlengths 1 6 | pn stringclasses 996
values | title stringclasses 871
values | pbdt int64 20.2M 20.3M | status int64 1 225 ⌀ | family_country listlengths 1 55 | modified_info stringlengths 112 8.31k ⌀ |
|---|---|---|---|---|---|---|---|
ggtgaagaagatcgacagctt | 1075 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
ggtgaagaagatcgacagctt | 1075 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
ggtgaagaagatcgacagctt | 1075 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
ggtgaagaagatcgacagctt | 1342 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
ggtgaagaagatcgacagctt | 1342 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
ggtgaagaagatcgacagctt | 1342 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
ttatccaggactctgtcaatttc | 2339 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
ttatccaggactctgtcaatttc | 2339 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
ttatccaggactctgtcaatttc | 2339 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
ttatccaggactctgtcaatttc | 3009 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
ttatccaggactctgtcaatttc | 3009 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
ttatccaggactctgtcaatttc | 3009 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
aatgccatttttgcacagtgtta | 1687 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
aatgccatttttgcacagtgtta | 1687 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
aatgccatttttgcacagtgtta | 1687 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
aatgccatttttgcacagtgtta | 930 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
aatgccatttttgcacagtgtta | 930 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
aatgccatttttgcacagtgtta | 930 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
gattctactttgaaaatgctttg | 6130 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
gattctactttgaaaatgctttg | 6130 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
gattctactttgaaaatgctttg | 6130 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
gattctactttgaaaatgctttg | 5224 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
gattctactttgaaaatgctttg | 5224 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
gattctactttgaaaatgctttg | 5224 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
tttggccttagcatggtacattg | 655 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"infos":["OTHER","5'-methyluridine-3'-phosphate"],"locations":["2->2"],"norInfos":[{"norInfo":[{"modificationType":"Other"}],"sourceData":"OTHER"},{"norInfo":[{"modification":["Phosphate"],"modificationType":"Chemical"}],"sourceData":"5'-methyluridine-3'-phosphate"}]}] |
tttggccttagcatggtacattg | 727 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methyluridine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["um"]},{"modificationType":"Chemical","modification":["Phosphorothioate"]}]}],"locations":["1->1"],"infos":["OTHER","2'-O... |
tttggccttagcatggtacattg | 637 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
gagccgttctctacaattact | 119 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gagccgttctctacaattact | 39 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
gagccgttctctacaattact | 29 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
gagccgttctctacaattact | 38 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
gagccgttctctacaattact | 30 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
gagccgttctctacaattact | 121 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gagccgttctctacaattact | 90 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
gagccgttctctacaattact | 142 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gagccgttctctacaattact | 147 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gagccgttctctacaattact | 127 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gagccgttctctacaattact | 124 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gagccgttctctacaattact | 57 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
gagccgttctctacaattact | 34 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
gagccgttctctacaattact | 148 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gagccgttctctacaattact | 37 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
gagccgttctctacaattact | 122 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gagccgttctctacaattact | 180 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gagccgttctctacaattact | 137 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gagccgttctctacaattact | 47 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
gagccgttctctacaattact | 53 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
gagccgttctctacaattact | 120 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gagccgttctctacaattact | 36 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
gagccgttctctacaattact | 123 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gagccgttctctacaattact | 125 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gagccgttctctacaattact | 126 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gagccgttctctacaattact | 143 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gagccgttctctacaattact | 35 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
gagccgttctctacaattact | 56 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
gagccgttctctacaattact | 146 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gagccgttctctacaattact | 58 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
gagccgttctctacaattact | 31 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
gagccgttctctacaattact | 145 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gagccgttctctacaattact | 33 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
gagccgttctctacaattact | 32 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
gagccgttctctacaattact | 129 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gagccgttctctacaattact | 55 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
gagccgttctctacaattact | 128 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylguanosine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["gm"]},{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos... |
gagccgttctctacaattact | 52 | JP2024535850A | 補体成分(C3)をサイレンシングするためのiRNA組成物および方法 | 20,241,002 | 2 | [
"JP",
"US",
"WO",
"EP"
] | null |
ctgaccatttcagaacatcttcc | 4438 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
ctgaccatttcagaacatcttcc | 4438 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
ctgaccatttcagaacatcttcc | 4438 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
ctgaccatttcagaacatcttcc | 3682 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
ctgaccatttcagaacatcttcc | 3682 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
ctgaccatttcagaacatcttcc | 3682 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
atctcttttctttatcctgtt | 5807 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methyladenosine-3'-phosphorothioate","norInfo":[{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos":["OTHER","2'-O-methyladenosine-3'-phosphorothioate"]},{"norI... |
atctcttttctttatcctgtt | 5807 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methyladenosine-3'-phosphorothioate","norInfo":[{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos":["OTHER","2'-O-methyladenosine-3'-phosphorothioate"]},{"norI... |
atctcttttctttatcctgtt | 5807 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methyladenosine-3'-phosphorothioate","norInfo":[{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos":["OTHER","2'-O-methyladenosine-3'-phosphorothioate"]},{"norI... |
atctcttttctttatcctgtt | 4859 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methyladenosine-3'-phosphorothioate","norInfo":[{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos":["OTHER","2'-O-methyladenosine-3'-phosphorothioate"]},{"norI... |
atctcttttctttatcctgtt | 4859 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methyladenosine-3'-phosphorothioate","norInfo":[{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos":["OTHER","2'-O-methyladenosine-3'-phosphorothioate"]},{"norI... |
atctcttttctttatcctgtt | 4859 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methyladenosine-3'-phosphorothioate","norInfo":[{"modificationType":"Chemical","modification":["Phosphorothioate","2'-O-methyl"]}]}],"locations":["1->1"],"infos":["OTHER","2'-O-methyladenosine-3'-phosphorothioate"]},{"norI... |
atctcttttctttatcctgtt | 4500 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
atctcttttctttatcctgtt | 4500 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
atctcttttctttatcctgtt | 4500 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
atctcttttctttatcctgtt | 5457 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
atctcttttctttatcctgtt | 5457 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
atctcttttctttatcctgtt | 5457 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
cctctgaatggtccagggtta | 2787 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylcytidine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["cm"]},{"modificationType":"Chemical","modification":["Phosphorothioate"]}]}],"locations":["1->1"],"infos":["OTHER","2'-... |
cctctgaatggtccagggtta | 2787 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylcytidine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["cm"]},{"modificationType":"Chemical","modification":["Phosphorothioate"]}]}],"locations":["1->1"],"infos":["OTHER","2'-... |
cctctgaatggtccagggtta | 2787 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylcytidine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["cm"]},{"modificationType":"Chemical","modification":["Phosphorothioate"]}]}],"locations":["1->1"],"infos":["OTHER","2'-... |
cctctgaatggtccagggtta | 2521 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
cctctgaatggtccagggtta | 2521 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
cctctgaatggtccagggtta | 2521 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
cctctgaatggtccagggtta | 2161 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylcytidine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["cm"]},{"modificationType":"Chemical","modification":["Phosphorothioate"]}]}],"locations":["1->1"],"infos":["OTHER","2'-... |
cctctgaatggtccagggtta | 2161 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylcytidine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["cm"]},{"modificationType":"Chemical","modification":["Phosphorothioate"]}]}],"locations":["1->1"],"infos":["OTHER","2'-... |
cctctgaatggtccagggtta | 2161 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"2'-O-methylcytidine-3'-phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["cm"]},{"modificationType":"Chemical","modification":["Phosphorothioate"]}]}],"locations":["1->1"],"infos":["OTHER","2'-... |
cctctgaatggtccagggtta | 1893 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
cctctgaatggtccagggtta | 1893 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
cctctgaatggtccagggtta | 1893 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
tgctacaacctctagatctgcag | 4363 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
tgctacaacctctagatctgcag | 4363 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
tgctacaacctctagatctgcag | 4363 | EP4416284A1 | COMPOSITIONS D'ARNI À ADMINISTRATION EXTRA-HÉPATIQUE ET LEURS PROCÉDÉS D'UTILISATION | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
tgctacaacctctagatctgcag | 3777 | EP4416284A1 | Extra-hepatic delivery irna compositions and methods of use thereof | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
tgctacaacctctagatctgcag | 3777 | EP4416284A1 | EXTRAHEPATISCHE IRNA-ZUSAMMENSETZUNGEN ZUR ABGABE UND VERFAHREN ZUR VERWENDUNG DAVON | 20,240,821 | 1 | [
"JP",
"NZ",
"EA",
"SG",
"CN",
"MX",
"AU",
"IN",
"US",
"EP",
"WO",
"HK",
"IL",
"ZA",
"CA",
"KR"
] | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.